Progressing PSA, defined as two consecutive increases in the most recent PSA measurements taken at least 1 week apart.
Progressed on Androgen Deprivation Therapy (ADT) and at least one prior potent Androgen Receptor (AR) pathway inhibitor given in castration-sensitive prostate cancer setting or approved for castration-resistant prostate cancer (eg, apalutamide, darolutamide, abiraterone, enzalutamide).
Ongoing primary ADT with gonadotropin-releasing hormone agonist or antagonist in the absence of bilateral orchiectomy.
Acceptable physical functioning and laboratory measurements, per the study protocol.
Discontinued prior therapies within protocol-specified timeframes.
Commit to use of highly-effective contraception while on study and for 90 days after.
Willing and able to adhere to the study visit schedule and other protocol defined requirements.
Any evidence of severe or uncontrolled systemic diseases.
Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results.
You may not be if
Predominance of small cell carcinoma of the prostate/neuroendocrine prostate cancer in most recent tumor biopsy.
Participants with brain metastases that require ongoing treatment with radiation or high-dose steroids.
Not recovered from side effects of prior surgery or cancer treatments.
Evidence of active viral, bacterial, or fungal infection requiring treatment with antivirals, antibiotics, or anti-fungal medications.
Prior treatment with AR degraders and molecules with an AR ligand such as AR Regulated Induced Proximity Targeting Chimera (RIPTAC).
Blood clots ≤ 4 weeks prior to start of treatment.
